Vnitr Lek 2022, 68(8):493-497 | DOI: 10.36290/vnl.2022.106

Venous thromboembolism in antiphosholipid syndrome

Alena Buliková, Miroslav Penka
Oddělení klinické hematologie Fakultní nemocnice Brno
Interní hematologická a onkologická klinika Masarykovy univerzity v Brně

Antiphosholipid syndrome (APS) is defined by the presence of clinical and laboratory criteria, it means by presence of antiphospholipid antibodies. Venous thromboembolism belongs to the most frequent clinical manifestation of this syndrome. Here we summarised basic pathophysiological mechanisms of venous thrombosis and lung embolism development, epidemiology of APS, and also the situations when this syndrome should be considered. The possible difficulties of laboratory diagnosis and their therapy involvement are mentioned.

Keywords: antiphospholipid syndrome, diagnose, treatment.

Accepted: December 1, 2022; Published: December 6, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Buliková A, Penka M. Venous thromboembolism in antiphosholipid syndrome. Vnitr Lek. 2022;68(8):493-497. doi: 10.36290/vnl.2022.106.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Miyakis S, Lockshin D, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306. Go to original source... Go to PubMed...
    2. Garcia D, Erkan D. Diagnosis and management of the antiphosholipid syndrome. NEJM. 2018;378:2010-2021. Go to original source... Go to PubMed...
    3. Rumsey DG, Myones B, Massicotte P. Diagnosis and treatment of antiphosholipid syndrome in childhood: A review. Blood Cells Mol, DiS. 2017;67:34-40. Go to original source... Go to PubMed...
    4. Rauch et al. Origin of antiphoshopilid antibodies. In Ercan G, Loschin MD. Antiphosholipid syndrome. Current research highlights and clinical insights. Springer international publishing 2017; pp 29-52. DOI: 1007/978-319-55442-6. Go to original source...
    5. Taha M, Samavati L. Antiphosholipid antibodies in COVID-19: a meta‑analysis and systematic review. RMD Open 2021;7:e001580. Go to original source... Go to PubMed...
    6. Risse J, Viera M, Beuret F et al. Reversible drug‑induced antiphosholipid syndrome. Lupus. 2018;27:333-33. Go to original source... Go to PubMed...
    7. Malý R, Masopust J, Hosák L, Konupčíková K. Assessment of a risk of a venous thromboembolism and its possible prevention in psychiatric patients. Psychiatry Clin Neurosci. 2008;62:3-8 Go to original source... Go to PubMed...
    8. Duarte‑Garcia A, Pham MM, Crowson CS et al. The epidemiology of antipshopholipid syndrome: A population‑based study. Arthrit Rheumatol. 2019; 71:1545-1552 Go to original source... Go to PubMed...
    9. Miranda S, Park J, Le Gal G et al. Prevalence of confirmed antiphosholipid syndrome in 18-50 years unselected patients with first unprovoked venous thromboembolism. J Thromb Haemost. 2020;18:916-930. Go to original source... Go to PubMed...
    10. Cervera R, Serrano R, Pons‑Estel GI et al. Morbidity and mortality in the antiphosholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheumat, DiS. 2015;74:1011-1018. Go to original source... Go to PubMed...
    11. Pengo V, Ruffatti A, Lenani C et al. Clinical course of high‑risk patients diagnosed with antiphosholipid syndrome. J Thromb Haemost. 2009;8:237-242. Go to original source... Go to PubMed...
    12. Tektonidou MG, Andreoli L, Limper M et a. EULAR recommendations for the management of antiphosholipid syndrome in adults. Ann Rheum, DiS. 2019;78:1296-1304. Go to original source... Go to PubMed...
    13. Zuily S, Cohen H, Isenbergr D et al. Use of direct oral anticoagulants in patients with thrombotic antiphosholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2020;18:2126-2137. Go to original source... Go to PubMed...
    14. Pengo V, Denas D, Zopplellaro G et al. Rivaroxaban vs warfarin in high risk patients with antiphospholipid syndrome. Blood 2018. doi: 10.1182/Blood-2018-04-848333. Go to original source... Go to PubMed...
    15. ASTRO‑APS investigators. Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Advances 2021. doi: 10.1182/bloodadvances.2021005808/1829277 Go to original source...
    16. Pastori D, Menichelli D, Cammisotto V, Pignatelli P. Use of direct oral anticoagulants in patients with antiphosholipid syndrome: A systematic review and comparison of the international Guidelines. Front Cardiovasc Med. 2021; doi: 10.3389/fcvm.2021. 715878. Go to original source... Go to PubMed...
    17. Cohen H, Cuadrado MJ, Erkan D et al. 16th International congress on antiphosholipid antibodies task force report on antiphosholipid antibodies treatment trends. Lupus. 2020;29:1571-1593. Go to original source... Go to PubMed...
    18. Keeling D, Mackie I, Moore GW et al. Guidelines on the investigation and management of antiphospholipid syndrome. BJH 2012;157:47-58. Go to original source... Go to PubMed...
    19. Pengo V, Tripodi A, Reber G et al. Up‑date of the guidelines for lupus anticoagulant detection. J |Thromb Haemost. 2009;7:1737-1740. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.